• Deuterium-Labeled Degarelix: What the Synthesis Shows

  2026-11-13

  A paper-centred interpretation of a synthetic chemistry study that used deuterium incorporation to create a mass-distinct degarelix acetate reference material. The evidence supports chemical feasibility and analytical characterization, while leaving biological and clinical questions outside the study’s scope.

• ACE2–MasR–Sirt1 Signaling in Septic Cardiomyopathy

  2026-11-13

  A paper-centred interpretation of a mouse study examining whether pharmacological ACE2 perturbation changes sepsis-associated cardiac injury and whether the response is linked to MasR–Sirt1-regulated mitochondrial biogenesis.

• ACE2–MasR Signaling in Septic Cardiomyopathy

  2026-11-12

  A mouse study examined whether pharmacological ACE2 activation or inhibition alters sepsis-associated cardiac injury. Its findings connect ACE2 activity with MasR-Sirt1-linked mitochondrial biogenesis, while leaving the pathway’s causal and translational significance open.

• Reciprocal Glial Signaling After Spinal Injury

  2026-11-12

  A mouse study identifies a reciprocal signaling circuit in which astrocyte-derived CSF1 supports lesion-associated microglia, while microglial IFN-β supports astrocyte survival and coordinated tissue repair. Genetic disruption and rescue experiments indicate that these pathways cooperate but are not interchangeable.

• ACE2–MasR–Sirt1 Signaling in Septic Cardiomyopathy

  2026-11-11

  A mouse study investigated whether ACE2 signaling influences sepsis-induced cardiac injury and whether MasR–Sirt1-associated mitochondrial biogenesis explains the observed effects. The findings support a preclinical mechanistic model, while remaining limited by the animal model and pharmacological nature of the perturbations.

• ACE2, Mitochondria, and Septic Cardiomyopathy

  2026-11-11

  A mouse study examined whether pharmacological ACE2 activation changes sepsis-induced cardiomyopathy and whether the effect is linked to MasR-Sirt1-mediated mitochondrial biogenesis. The findings support a mechanistic association in the experimental model, while leaving questions about direct causality and translation to human sepsis.

• ACE2, Mitochondria, and Septic Cardiomyopathy

  2026-11-10

  An in vivo mouse study examined whether pharmacological ACE2 modulation changes sepsis-induced cardiomyopathy and whether the response is associated with MasR-Sirt1-mediated mitochondrial biogenesis. The findings support a mechanistic association between ACE2 activity, cardiac stress responses, and mitochondrial regulation, while remaining limited by the pharmacological and mouse-model design.

• ACE2–MasR Signaling in Septic Cardiomyopathy

  2026-11-10

  A mouse study investigated whether pharmacological ACE2 modulation changes sepsis-associated cardiac injury and whether the response is linked to MasR-Sirt1-mediated mitochondrial biogenesis. The findings support a model in which ACE2 signaling is connected to cardiac function, inflammation, oxidative stress, apoptosis, and mitochondrial regulation, while remaining limited to an experimental sepsis model.

• ACE2–MasR–Sirt1 in Septic Cardiomyopathy

  2026-11-09

  A mouse study examined whether ACE2 modulation changes sepsis-associated cardiac injury and whether MasR–Sirt1-linked mitochondrial biogenesis provides a mechanistic explanation. The findings support a pathway-associated interpretation while remaining limited to an experimental model.

• Wnt, O-GlcNAcylation, and Bone Formation

  2026-11-09

  A preclinical study connects Wnt signaling to O-GlcNAcylation-dependent glycolytic reprogramming, identifying PDK1 as a possible mechanistic link between metabolism and osteoblastogenesis.

• Multiplexed CRISPR–Cas: What the Evidence Shows

  2026-11-08

  A paper-centred interpretation of how multiplexed CRISPR–Cas systems have been used for multi-target editing, structural-variant generation, gene regulation, functional screening and selective cellular analysis, with emphasis on evidence strength and study limitations.

• ACE2, Mitochondria and Septic Cardiac Injury

  2026-11-07

  A paper-centred interpretation of a mouse study examining whether ACE2 signaling influences sepsis-induced cardiomyopathy through MasR-Sirt1-associated mitochondrial biogenesis.

• ACE2 and Mitochondrial Biogenesis in Septic Heart Injury

  2026-11-06

  A mouse study tested whether pharmacological ACE2 perturbation changes sepsis-associated cardiac injury, focusing on MasR-Sirt1-linked mitochondrial biogenesis. The findings support a model in which ACE2 signaling tracks with cardiac functional, inflammatory, oxidative-stress, and apoptotic responses, while leaving translation and pathway causality unresolved.

• ACE2–MasR Signaling in Septic Cardiomyopathy

  2026-11-06

  A mouse study examined whether pharmacological ACE2 activation or inhibition changes sepsis-associated cardiac injury. Its findings connected ACE2 activation with MasR-Sirt1 signaling, mitochondrial biogenesis, and coordinated changes in cardiac function, inflammation, oxidative stress, apoptosis, and survival.

• ACE2, Mitochondrial Biogenesis and Septic Heart Injury

  2026-11-05

  A mouse study examined whether pharmacological ACE2 modulation changes sepsis-associated cardiac injury and whether MasR-Sirt1-linked mitochondrial biogenesis helps explain the observed pattern. The findings support a model-specific mechanistic hypothesis relevant to ACE2 activation research and mitochondrial biogenesis studies, while remaining limited for clinical interpretation.

7849 records 1/524 page Next 12345 下5页 Last page